NANOENCAPSULATION AUGMENTS RELEASE EFFICACY AND GLUCOSE TOLERANCE OF 14-DEOXY, 11, 12-DIDEHYDRO ANDROGRAPHOLIDE LOADED POLYCAPROLACTONE NANOPARTICLES IN STREPTOZOTOCIN-NICOTINAMIDE INDUCED TYPE 2 DIABETES

Authors

  • Nagalakshmi K. Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203
  • Sujatha S. Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203

DOI:

https://doi.org/10.22159/ijap.2017v9i6.21607

Keywords:

DDA, Nanoencapsulation, Release efficacy, Plasma glucose, Antihyperglycemic activity, Bioavailability

Abstract

Objective: This study was designed to study the release efficacy and glucose tolerance of 14-deoxy, 11, 12-didehydroandrographolide loaded polycaprolactone nanoparticles in streptozotocin-nicotinamide induced type 2 diabetes.

Methods: Biodegradable polymer based novel drug delivery systems had brought a considerable attention to improve therapeutic efficacy and bioavailability of various drugs. In this study, 14-deoxy-11, 12-didehydroandrographolide (sparingly water soluble) loaded polycaprolactone (nano-DDA) was synthesized using polyvinyl alcohol and tween20 as surfactants. MTT assay was performed to analyse the cytotoxicity of both the formulations on L6 myoblasts. Free DDA and nano-DDA were administered orally to the streptozotocin-nicotinamide induced experimental diabetic rats for 45d. Oral glucose tolerance test (OGTT) was carried out at the end of the study. After one week washout period, animals were administered with free and nano-DDA and release efficacy of DDA from polymer matrix and concentration of glucose were analysed.

Results: MTT assay revealed that nano-DDA prepared using tween-20 as a surfactant elicited cytotoxicity towards L6 myoblasts, whereas nano-DDA prepared using polyvinyl alcohol as a surfactant remained non-toxic till 10µM. OGTT studies revealed an initial increase of glucose at 30 min followed by a progressive decrease in the glucose level. In rat plasma, a gradual decrease in glucose level was observed up to 32h (139 mg/dl) for free DDA, whereas nano-DDA exhibited a major decrease in glucose concentration at 32h (115 mg/dl) which continued even after 48h (117 mg/dl).

Conclusion: A slow and sustained release of DDA from the polymer matrix substantiated that nanoencapsulation enhanced the oral bioavailability of DDA which resulted in decreasing the concentration of glucose which could be due to the pronounced antihyperglycemic activity of nano-DDA over free DDA.

Downloads

Download data is not yet available.

References

Samadder A, Das S, Das J, Khuda-Bukhsh AR. Relative efficacies of insulin and poly (lactic-co-glycolic) acid encapsulated nano-insulin in modulating certain significant biomarkers in arsenic intoxicated L6 cells. Colloids Surf B 2013;109:10–9.

Vijayan M, Jose R, Jose S, Abraham S, Joy J. Study on quality of life assessment in diabetic retinopathy among patients with type 2 diabetic patients. Asian J Pharm Clin Res 2017;10:116–9.

IDF diabetes atlas-Home n.d. Available from: http:// www.diabetesatlas.org. [Last accessed on 13 Jun 2017].

Kumar R, Patel D, Prasad S, Sairam K, Hemalatha S. Antidiabetic activity of alcoholic root extract of Caesalpinia digyna in streptozotocin-nicotinamide-induced diabetic rats. Asian Pac J Trop Biomed 2012;2:S934–40.

Erel G, Kotmakçı M, Akbaba H, Sozer Karadaglı S, Kantarcı AG. Nanoencapsulated chitosan nanoparticles in the emulsion-based oral delivery system: in vitro and in vivo evaluation of insulin loaded formulation. J Drug Delivery Sci Technol 2016;36:161–7.

Dhana Lekshmi UM, Poovi G, Neelakanta Reddy P. In vitro observation of repaglinide engineered polymeric nanoparticles. Dig J Nanomater Biostructures 2012;7:1–18.

Mahapatro A, Singh DK. Biodegradable nanoparticles are an excellent vehicle for site-directed in vivo delivery of drugs and vaccines. J Nanobiotechnol 2011;9:55.

Soonthornsit N, Hemstapat W, Pitaksutheepong C, Pitaksuteepong T. Enhancement of stability, release and in vitro digestibility of mulberrystem extract using microemulsions. Int J Pharm Pharm Sci 2017;9:103–9.

Nizar Awish Jassem NAR. Formulation and in vitro evaluation of Azilasartan medoxomil nanosuspension. Int J Pharm Pharm Sci 2017;9:110-9.

Dash TK, Konkimalla VB. Poly-є-caprolactone based formulations for drug delivery and tissue engineering: a review. J Controlled Release 2012;158:15–33.

Ooi JP, Kuroyanagi M, Sulaiman SF, Muhammad TST, Tan ML. Andrographolide and 14-deoxy-11, 12-didehydroandrographolide inhibit cytochrome P450s in HepG2 hepatoma cells. Life Sci 2011;88:447–54.

Nagalakshmi K, S Sujatha, D Alwin. DDA loaded PCL nanoparticles enhances the oral bioavailability of DDA in diabetes-induced experimental rats. Int J Pharm Pharm Sci 2017;9:198.

Al-marzook FA, Omran R. Cytotoxic activity of alkaloid extracts of different plants against breast cancer cell line. Asian J Pharm Clin Res 2017;10:168–71.

Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005;11:127–52.

Fröde TS, Medeiros YS. Animal models to test drugs with potential antidiabetic activity. J Ethnopharmacol 2008;115:173–83.

Sarvesh Sharma, Vimal Kumar. In vitro cytotoxicity effect on MCF-7 cell line of co-encapsulated artesunate and curcuminliposome. Int J Pharm Pharm Sci 2017;9:123-8.

Pari L, Saravanan G. Antidiabetic effect of cogent db, a herbal drug in alloxan-induced diabetes mellitus. Comp Biochem Physiol-C Toxicol Pharmacol 2002;131:19–25.

Kamaraj N, Rajaguru PY, Issac P kumar, Sundaresan S. Fabrication, characterization, in vitro drug release and glucose uptake activity of 14-deoxy, 11, 12-didehydroandrographolide loaded polycaprolactone nanoparticles. Asian J Pharm Sci 2017;12:353-62.

Nasiri Zadeh S, Rajabnezhad S, Zandkarimi M, Dahmardeh S, Mir L, Ali Darbandi M, et al. Mucoadhesive microspheres of chitosan and polyvinyl alcohol as a carrier for intranasal delivery of insulin: in vitro and in vivo studies. MOJ Bioequiv Availab 2017;3:1-8.

Jain NK, Jain SK. Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin. AAPS PharmSciTech 2010;11:686–97.

Ihekwereme C, Esimone C, Shao D, Agu RU. Preliminary studies on validation of calu-3 cell line irritation and toxicity. Pharmaceutics 2014;6:268–80.

Atefeh Hekmat, Hossein Attar, Ali Akbar Seyf Kordi, Maryam Iman, JmR aafari. New oral formulation and in vitro evaluation of docetaxel-loaded nanomicelles. Molecules 2016;21:17–9.

Vimala K, Yallapu MM, Varaprasad K, Reddy NN, Ravindra S, Naidu NS, et al. Fabrication of curcumin encapsulated chitosan-PVA silver nanocomposite films for improved antimicrobial activity. J Biomater Nanobiotechnol 2011;2:55–64.

Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Controlled Release 2002;82:105–14.

Ling Y, Huang Y. Preparation and release efficiency of poly (lactic-co-glycolic) acid nanoparticles for drug-loaded paclitaxel. 7th asian-pacific conf. Med Biol Eng Berlin Heidelberg: Springer Berlin Heidelberg; 2008. p. 514–7.

Liu Z, Wan L, Yue Y, Xiao Z, Zhang Y, Wang Y, et al. Hypoglycemic activity and antioxidative stress of extracts and corymbiferin from swertia bimaculata in vitro and in vivo. Evid Based Complement Altern Med 2013:1–12. http://dx.doi.org/10.1155/2013/125416

Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Controlled Release 2000;65:261–9.

Song L, Zhi Z, Pickup JC. Nanolayer encapsulation of insulin-chitosan complexes improves the efficiency of oral insulin delivery. Int J Nanomed 2014;9:2127–36.

Seema K, Megha S, Abhisek P. Ethylcellulosefloating microspheres of antidiabetic agent: in vitro and in vivo evaluation. Int J Appl Pharm 2017;9:44-9.

Published

07-11-2017

How to Cite

K., N., & S., S. (2017). NANOENCAPSULATION AUGMENTS RELEASE EFFICACY AND GLUCOSE TOLERANCE OF 14-DEOXY, 11, 12-DIDEHYDRO ANDROGRAPHOLIDE LOADED POLYCAPROLACTONE NANOPARTICLES IN STREPTOZOTOCIN-NICOTINAMIDE INDUCED TYPE 2 DIABETES. International Journal of Applied Pharmaceutics, 9(6), 49–53. https://doi.org/10.22159/ijap.2017v9i6.21607

Issue

Section

Original Article(s)

Most read articles by the same author(s)